Trial for active or high-risk smoldering myeloma treatments
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 2 study tests a treatment approach for adults with active multiple myeloma (MM) or a high/intermediate-risk “smoldering” MM that hasn’t been treated yet. It may help by trying to control the disease earlier or more effectively, depending on what the trial drug(s) do.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older
- Have active multiple myeloma, or untreated smoldering myeloma that meets specific lab/body criteria (not low-risk)
- Have recent lab results (within 30 days): kidney function clearance ≥30, neutrophils >1000, platelets >75,000, and hemoglobin ≥8
- Have measurable disease on tests (blood or urine protein and/or abnormal free light chain results)
- Be able to do trial blood tests and visits, and have an estimated life expectancy of more than 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a precision approach to treat people with high-risk smoldering myeloma (a condition that can turn into active myeloma). The goal is to see whether the treatment can slow or prevent progression and improve outcomes.
This trial tests two immunotherapy drugs (teclistamab and daratumumab) for people with high-risk smoldering myeloma to see if the combination can stop or delay progression to active multiple myeloma. It's a new approach for those whose smoldering myeloma has a higher chance of becoming active.
This trial tests a new drug called Elranatamab for people with a high-risk form of smoldering multiple myeloma (SMM). The goal is to see if the drug can prevent or delay the progression to active multiple myeloma.
This trial watches people with a high-risk form of smoldering myeloma (an early, inactive stage of bone marrow cancer) to learn more about how it changes. It may help doctors know who needs treatment later.
This early-phase study tests how safe and effective several treatment approaches are for people with multiple myeloma who have already had other treatments. Depending on your myeloma features and prior care, a study drug combination may be offered to try to control the disease.
This Phase 1/2 trial tests a cancer vaccine (TG01/QS-21) in people with high-risk smoldering multiple myeloma or multiple myeloma. It aims to see how safe the vaccine is and whether it can help the immune system control the disease.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.